91MO Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study.
Saved in:
| Title: | 91MO Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study. |
|---|---|
| Authors: | Kuboki, Y.1 (AUTHOR), Pietrantonio, F.2 (AUTHOR), Salvatore, L.3 (AUTHOR), Esaki, T.4 (AUTHOR), Modest, D.P.5 (AUTHOR), Paez, D.6 (AUTHOR), Taieb, J.7 (AUTHOR), Ruiz, E.8 (AUTHOR), Kim, T.W.9 (AUTHOR), Meriggi, F.A.10 (AUTHOR), Cunningham, D.11 (AUTHOR), Yeh, K-H.12 (AUTHOR), Chan, E.13 (AUTHOR), Chao, J.14 (AUTHOR), Strydom, N.15 (AUTHOR), Saportas, Y.16 (AUTHOR), Tran, Q.17 (AUTHOR), Cremolini, C.18 (AUTHOR), Fakih, M.19 (AUTHOR) |
| Source: | Annals of Oncology. 2023 Supplement 4, Vol. 34, pS1504-S1505. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2023.10.226 |
